
NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.
NRx Pharmaceuticals is set to report quarterly earnings with an expected loss of $0.09 per share and revenue of $1.33 million, reflecting ongoing financial challenges. Despite negative profitability and cash flow metrics, the company received positiv...

